Historical Valuation
Telomir Pharmaceuticals Inc (TELO) is now in the Fair zone, suggesting that its current forward PS ratio of 92.14 is considered Fairly compared with the five-year average of -5.83. The fair price of Telomir Pharmaceuticals Inc (TELO) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.36
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Telomir Pharmaceuticals Inc (TELO) has a current Price-to-Book (P/B) ratio of 6.50. Compared to its 3-year average P/B ratio of 63.06 , the current P/B ratio is approximately -89.70% higher. Relative to its 5-year average P/B ratio of 63.06, the current P/B ratio is about -89.70% higher. Telomir Pharmaceuticals Inc (TELO) has a Forward Free Cash Flow (FCF) yield of approximately -6.71%. Compared to its 3-year average FCF yield of -4.84%, the current FCF yield is approximately 38.68% lower. Relative to its 5-year average FCF yield of -4.84% , the current FCF yield is about 38.68% lower.
P/B
Median3y
63.06
Median5y
63.06
FCF Yield
Median3y
-4.84
Median5y
-4.84
Competitors Valuation Multiple
AI Analysis for TELO
The average P/S ratio for TELO competitors is 33.15, providing a benchmark for relative valuation. Telomir Pharmaceuticals Inc Corp (TELO.O) exhibits a P/S ratio of 92.14, which is 177.94% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TELO
1Y
3Y
5Y
Market capitalization of TELO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TELO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TELO currently overvalued or undervalued?
Telomir Pharmaceuticals Inc (TELO) is now in the Fair zone, suggesting that its current forward PS ratio of 92.14 is considered Fairly compared with the five-year average of -5.83. The fair price of Telomir Pharmaceuticals Inc (TELO) is between to according to relative valuation methord.
What is Telomir Pharmaceuticals Inc (TELO) fair value?
TELO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Telomir Pharmaceuticals Inc (TELO) is between to according to relative valuation methord.
How does TELO's valuation metrics compare to the industry average?
The average P/S ratio for TELO's competitors is 33.15, providing a benchmark for relative valuation. Telomir Pharmaceuticals Inc Corp (TELO) exhibits a P/S ratio of 92.14, which is 177.94% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Telomir Pharmaceuticals Inc (TELO) as of Jan 09 2026?
As of Jan 09 2026, Telomir Pharmaceuticals Inc (TELO) has a P/B ratio of 6.50. This indicates that the market values TELO at 6.50 times its book value.
What is the current FCF Yield for Telomir Pharmaceuticals Inc (TELO) as of Jan 09 2026?
As of Jan 09 2026, Telomir Pharmaceuticals Inc (TELO) has a FCF Yield of -6.71%. This means that for every dollar of Telomir Pharmaceuticals Inc’s market capitalization, the company generates -6.71 cents in free cash flow.
What is the current Forward P/E ratio for Telomir Pharmaceuticals Inc (TELO) as of Jan 09 2026?
As of Jan 09 2026, Telomir Pharmaceuticals Inc (TELO) has a Forward P/E ratio of -4.62. This means the market is willing to pay $-4.62 for every dollar of Telomir Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Telomir Pharmaceuticals Inc (TELO) as of Jan 09 2026?
As of Jan 09 2026, Telomir Pharmaceuticals Inc (TELO) has a Forward P/S ratio of 92.14. This means the market is valuing TELO at $92.14 for every dollar of expected revenue over the next 12 months.